Wider use of clozapine, one of the most effective antipshychotic drugs, is precluded by its
propensity to cause agranulocytosis. Currently, clozapine is used for treatment-resistant …

These updated guidelines from the British Association for Psychopharmacology replace the
original version published in 2011. They address the scope and targets of pharmacological …

AimsClozapine is licensed for treatment-resistant psychosis and remains underutilised. This
may berelated to the stringent haematological monitoring requirements that are mandatory …

Objectives To identify the risks and benefits of clozapine‑lithium co-prescription. Methods
Articles published in English or French were identified with a MEDLINE, Web of Sciences …

After the introduction of clozapine eight Finnish patients died after developing
agranulocytosis. Clozapine was withdrawn from the market and only reintroduced with strict …

Background Clozapine is uniquely effective in treatment-resistant psychosis. In the UK,
patients must discontinue clozapine indefinitely if they are placed on the Central Non …

Drug-induced agranulocytosis is a life-threatening side effect that usually manifests as a
severe form of neutropenia associated with fever or signs of sepsis. It can occur as a …

Background: Clozapine is widely prescribed for treatment-refractory schizophrenia, but its
use is limited by many potentially life-threatening adverse effects. The risk of rechallenge …

Introduction: Clozapine was first introduced as an antipsychotic in the 1970's but a cluster of
deaths, later linked to the drug's risk of agranulocytosis, led to its withdrawal in most …

Clozapine is the only available treatment for refractory schizophrenia but its use involves
frequent physical contact with healthcare workers for the purpose of mandatory blood …